


Recent update in Left Main / Bifurcation

Jeehoon Kang

**Cardiology / Critical Care
Medicine, SNUH**



SEOUL NATIONAL UNIVERSITY
HOSPITAL


Distal Left Main Bifurcation

A Challenging Lesion Subset for PCI


- LMCA supplies perfusion for **more than half** of total myocardium
- Up to **80%** of LM lesion involves **distal LM bifurcation**
- Presents **poorer prognosis** compared to ostial or shaft lesion

The DELTA Registry: PS-Matched Analysis

MACE (Death, MI, TVR)



TLR



Distal Left Main Bifurcation

A Challenging Lesion Subset for PCI

Recommendation for the type of revascularization in patients with stable coronary artery disease with suitable coronary anatomy for both procedures and low predicted surgical mortality^d

Recommendations according to extent of CAD	CABG		PCI	
	Class ^a	Level ^b	Class ^a	Level ^b
One-vessel CAD				
Without proximal LAD stenosis.	IIb	C	I	C
With proximal LAD stenosis. ^{68,101,139-144}	I	A	I	A
Two-vessel CAD				
Without proximal LAD stenosis.	IIb	C	I	C
With proximal LAD stenosis. ^{68,70,73}	I	B	I	C
Left main CAD				
Left main disease with low SYNTAX score (0 - 22). ^{69,121,122,124,145-148}	I	A	I	A
Left main disease with intermediate SYNTAX score (23 - 32). ^{69,121,122,124,145-148}	I	A	IIa	A
Left main disease with high SYNTAX score (≥33). ^{c 69,121,122,124,146-148}	I	A	III	B
Three-vessel CAD without diabetes mellitus				
Three-vessel disease with low SYNTAX score (0 - 22). ^{102,105,121,123,124,135,149}	I	A	I	A
Three-vessel disease with intermediate or high SYNTAX score (>22). ^{c 102,105,121,123,124,135,149}	I	A	III	A
Three-vessel CAD with diabetes mellitus				
Three-vessel disease with low SYNTAX score 0-22. ^{102,105,121,123,124,135,150-157}	I	A	IIb	A
Three-vessel disease with intermediate or high SYNTAX score (>22). ^{c 102,105,121,123,124,135,150-157}	I	A	III	A

5.4 Gaps in the evidence

It remains to be determined whether revascularization by PCI improves prognosis in patients with SCAD. The ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) study (NCT01471522) is currently recruiting 5000 patients with SCAD and evidence of moderate-to-severe ischaemia detected by non-invasive imaging, who are randomized before coronary angiography to medical therapy or an invasive strategy to detect differences in the primary endpoint of death or MI. Current techniques rely on coronary angiography and the detection of ischaemia-producing lesions. However, future adverse events are related at least in part to non-flow limiting, vulnerable plaques. Better identification of vulnerable plaques and the development of appropriate treatment strategies is needed. Along the same lines, the completeness and timing of revascularization are not well defined, and neither are the roles of residual ischaemia and lesions. Moreover, we need more research on the use of the SYNTAX and other scores for informing treatment allocation, as well as dedicated trials in specific subsets. Very long-term, extended follow-up (10 years) of trials comparing PCI and CABG, particularly in the setting of LM disease, will provide further insights into the relative merits of both revascularization techniques.

Distal Left Main Bifurcation


PCI vs. CABG

ORIGINAL ARTICLE

Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease

G.W. Stone, A.P. Kappetein, J.F. Sabik, S.J. Pocock, M.-C. Morice, J. Puskas, D.E. Kandzari, D. Karpaliotis, W.M. Brown III, N.J. Lembo, A. Banning, B. Merkely, F. Horkay, P.W. Boonstra, A.J. van Boven, I. Ungi, G. Bogáts, S. Mansour, N. Noiseux, M. Sabaté, J. Pomar, M. Hickey, A. Gershlick, P.E. Buszman, A. Bochenek, E. Schampaert, P. Pagé, R. Modolo, J. Gregson, C.A. Simonton, R. Mehran, I. Kosmidou, P. Généreux, A. Crowley, O. Dressler, and P.W. Serruys, for the EXCEL Trial Investigators*

- ✓ Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial
- ✓ Unprotected LMCA disease with angiographic DS >70%, as estimated visually, or 50% ≤ DS < 70% with at least one of following: (1) noninvasive evidence of ischemia referable to LMCA lesion, (2) IVUS MLA ≤ 6.0 mm², or (3) FFR ≤ 0.80
- ✓ DES: XIENCE, Abbott Vascular vs. CABG





Distal Left Main Bifurcation

PCI vs. CABG

ORIGINAL ARTICLE

Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease



Conclusion>

- ✓ At the end of the 5-year follow-up period, event-free survival time was 5.2 days (95% CI -46.1 to 56.5 days) longer after PCI compared with CABG
- ✓ Ten-year follow-up (or longer) is required to characterize the very late safety profile of PCI and CABG as both stents and bypass grafts progressively fail over time

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials


Surgeon David Taggart set the EACTS meeting ablaze when he accused EXCEL researchers of stacking the deck in PCI's favor.




By [Michael O'Riordan](#) | October 07, 2019




Distal Left Main Bifurcation PCI vs. CABG



Overall completeness of follow-up: 94%



Treatment-by-Subgroup Interaction



- ✓ There is no MACCE free benefit of Surgery versus PCI with contemporary stents
- ✓ PCI had comparable 10y survival to CABG in patients with LM-disease.
- ✓ In subgroup analysis, No treatment difference in all-cause death with LM disease patients.


Distal Left Main Bifurcation

PCI vs. CABG

10-Year Outcomes of Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease



Duk-Woo Park, MD,^{a,*} Jung-Min Ahn, MD,^{a,*} Sung-Cheol Yun, PhD,^b Yong-Hoon Yoon, MD,^a Do-Yoon Kang, MD,^a Pil Hyung Lee, MD,^a Seung-Whan Lee, MD,^a Seong-Wook Park, MD,^a Ki Bae Seung, MD,^c Hyeon-Cheol Gwon, MD,^d Myung-Ho Jeong, MD,^e Yangsoo Jang, MD,^f Hyo-Soo Kim, MD,^g In-Whan Seong, MD,^h Hun Sik Park, MD,ⁱ Taehoon Ahn, MD,^j In-Ho Chae, MD,^k Seung-Jea Tahk, MD,^l Seung-Jung Park, MD^a



During a 10 year follow-up period


- ✓ MACE (all cause death, Q wave MI, Stroke) were comparable in PCI vs. CABG
- ✓ TVR was more common in the PCI arm (*which did not translate into hard endpoints*)

Distal Left Main Bifurcation PCI vs. CABG


10-Year Outcomes in Distal Left Main Coronary Artery Disease

Duk-Woo Park, MD,^{a,*} Jung-Min Park, MD,^a Pil Hyung Lee, MD,^a Seung-Won Park, MD,^a Myung-Ho Jeong, MD,^c Yangsoo Jang, MD,^b Tae-hoon Ahn, MD,^d In-Ho Cha, MD,^e


A




A Death from Any Cause



B Death, Q Wave Myocardial Infarction, or Stroke



C Target-Vessel Revascularization




During a 10-year follow-up, the cumulative incidence of MACE was significantly lower in the CABG group (21.4% vs. 23.4%, $P = .001$). The cumulative incidence of TVR was significantly lower in the CABG group (4.6% vs. 22.0%, $P < .001$).


Impact of New-Generation DES

EES vs SES in COBIS II


Overall bifurcation



LM bifurcation



LM bifurcation by 2-stent technique



Difference in performance between EES and SES for bifurcation lesion **becomes greater** when lesion is at LM and becomes more complex

Impact of New-Generation DES

Korean Bifurcation Pooled Cohort (3Y)


TLR of LM in **1st Generation DES**
(10.7% = 74 / 689 patients)

1-Stent Group
(5.5% = 22/397)

Diffuse ISR :
0.0%

2-Stent Group
(18% = 52/292)

Diffuse ISR :
1.9%




TLR of LM in **2nd Generation DES**
(5.6% = 12 / 214 patients)

1-Stent Group
(6.7% = 9/134)

Diffuse ISR :
0.0%

2-Stent Group
(4% = 3/80)


Diffuse ISR :
0.0%



Room for Improvement beyond Devices

Optimal Selection of PCI Strategy

DKCRUSH-V : Outcomes By Lesion Complexity (3Y)



Room for Improvement beyond Devices

Optimal Selection of PCI Strategy

**EBC MAIN
(NCT02497014)**

Patient with left main stem true bifurcation lesion (1,1,1 or 0,1,1)
(LAD and Cx both >2.75 mm)

Suitable for stent treatment

Consent

Randomisation to either:

A: planned single-stent strategy

B: planned dual-stent strategy

**DEFINITION II
(NCT02284750)**

660 patients with complex coronary bifurcation lesions according to DEFINITION criteria

Major criteria:

For left main bifurcation (major 1)

- SB lesion length ≥ 10 mm, and
- SB-diameter stenosis $\geq 70\%$

For non-left main bifurcation (major 2)

- SB lesion length ≥ 10 mm, and
- SB-diameter stenosis $\geq 90\%$

Minor criteria:

- >Mild calcification
- Multiple lesions
- Bifurcation angle $< 45^\circ$ or $> 70^\circ$
- MV-RVD < 2.5 mm
- MV lesion length ≥ 25 mm
- Thrombus-containing lesions

major 1 or 2 + any two minors

Provisional Group (N=330)

1:1 Randomization

Two-stent Group (N=330)

Exclusions (N=4):

- 2 repeat random
- 1 worsening post-random
- 1 withdrew post-random

Exclusions (N=3):

- 1 repeat random
- 1 worsening post-random
- 1 withdrew post-random

Provisional Group (N=326)

Two-stent Group (N=327)

Angiography follow-up at 13 months

Safety endpoint: definite/probable stent thrombosis at 12 months follow-up




Primary endpoint: Target lesion failure (TLF) at 12 months follow-up



- Results of ongoing trials may help establish the optimal criteria for selecting LM bifurcation PCI strategy

Room for Improvement beyond Devices

Optimal Antithrombotic Management

IDEAL-LM

Synergy: <ul style="list-style-type: none"> Platinum-Chromium backbone Strut thickness: 74µm Biodegradable polymer Abluminal coating 	RCT 	XiencE: <ul style="list-style-type: none"> Cobalt-Chromium backbone Strut thickness: 81µm Permanent polymer Circumferential coating 
+ Short DAPT (4 months)		+ Standard DAPT (12 months)





Room for Improvement beyond Devices

Optimal Antithrombotic Management

IDEAL-LM

Synergy: <ul style="list-style-type: none"> Platinum-Chromium backbone Strut thickness: 74µm Biodegradable polymer Abluminal coating 	<div style="border: 1px solid white; padding: 2px; display: inline-block;">RCT</div> 	Xience: <ul style="list-style-type: none"> Cobalt-Chromium backbone Strut thickness: 81µm Permanent polymer Circumferential coating
+ Short DAPT (4 months)		+ Standard DAPT (12 months)



SynergyStentAnd4MonthsDapt	410	402	400	397	396	395	389	386	383	379	378	376	361
XienceStentAnd12MonthsDapt	408	401	397	395	392	392	390	381	379	379	377	377	362

Room for Improvement beyond Devices

Optimal Antithrombotic Management

Real-World Data of DAPT Duration after LM Bifurcation PCI in the New-Generation DES Era

JACC: CARDIOVASCULAR INTERVENTIONS

VOL. 11, NO. 24, 2018

© 2018 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION

PUBLISHED BY ELSEVIER

Dual Antiplatelet Therapy Duration Determines Outcome After 2- But Not 1-Stent Strategy in Left Main Bifurcation Percutaneous Coronary Intervention



Tae-Min Rhee, MD,^a Kyung Woo Park, MD, PhD,^a Chi-Hoon Kim, MD,^b Jeehoon Kang, MD,^a Jung-Kyu Han, MD, PhD,^a
Han-Mo Yang, MD, PhD,^a Hyun-Jae Kang, MD, PhD,^a Bon-Kwon Koo, MD, PhD,^a Hyo-Soo Kim, MD, PhD^a

SEOUL NATIONAL UNIVERSITY
HOSPITAL

Grand DES cohort

10 years of clinical excellence

Dedicated 3-year follow-up for contemporary DESs

Seoul National University Hospital &
other 55 centers across the country

Allocated stent(s)	Biomatrix/ Nobori/ Biomatrix Flex	Xience Prime	Xience V/ Promus	Resolute Integrity	Resolute
Enrollment	2010.4~2014.11.	2010.12~2012.8.	2008.4~2010.5.	2011.10~2014.7	2009.1~2010.6.
Patients	3007	2076	3078	3004	2007
Lesions	4137	2913	4184	4128	2806
Participating centers	24	26	29	22	25

13172 patients
18168 lesions

**Biolimus-
3000-Korea**

**Excellent
Prospective
Cohort**

**Resolute
Korea**


**Excellent
Prime**

Resolinte

1-stent vs 2-stent


Composite Outcomes at 3-Year

3-Year Target Lesion Failure



† Composite of cardiac death, target-vessel MI, and clinically-driven target lesion revascularization

3-Year Thrombotic MACE




‡ Composite of cardiac death, all-cause MI, and definite/probable stent thrombosis

Adjusted HR was calculated with multivariable Cox PH model, including covariates as follows:
Age, Gender, DM, CKD, Peripheral vascular disease, AMI at presentation, Previous history of PCI, LV dysfunction (EF <40%), 3-vessel disease, true bifurcation, severe calcification, in-stent restenosis, and type of stent (BP-BES, DP-EES, DP-ZES)

1-stent vs 2-stent by DAPT Duration

Target Lesion Failure

DAPT interruption < 1-year




DAPT maintenance ≥ 1-year



P for interaction = 0.012

Room for Improvement beyond Devices

Optimal Antithrombotic Management



- ✓ Some types of complex procedures (e.g., bifurcation PCI with 2 stents) are associated with higher thrombotic risk than others, which may require prolonged DAPT

Conclusion

- The optimal treatment option for distal LM disease, is still under controversy.
 - PCI vs CABG
- Regarding PCI, 2nd generation DES has improved the clinical outcome, while technical aspects are evolving.
 - More sophisticated devices and techniques
- Medical therapy, including prolonged DAPT, is essential in improving clinical outcomes.

Thank You For Your Attention

